Olivier Lortholary

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6379609/publications.pdf

Version: 2024-02-01

53794 14759 20,019 134 45 127 citations h-index g-index papers 136 136 136 16501 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1356-1364.e2.	3.8	2
2	An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: AAstudy of a national retrospective cohort of 1375 patients over 10 years. Journal of Allergy and Clinical Immunology, 2022, 149, 2116-2125.	2.9	7
3	Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. New England Journal of Medicine, 2022, 386, 1109-1120.	27.0	119
4	Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS Mutations. Antimicrobial Agents and Chemotherapy, 2022, 66, e0172521.	3.2	6
5	Case Report: Invasive Cryptococcosis in French Guiana: Immune and Genetic Investigation in Six Non-HIV Patients. Frontiers in Immunology, 2022, 13, 881352.	4.8	1
6	Identification of <i>Streptomyces</i> spp. in a Clinical Sample: Always Contamination? Results of a French Retrospective Study. Open Forum Infectious Diseases, 2022, 9, .	0.9	1
7	Infections in Patients with Chronic Granulomatous Disease Treated with Tumor Necrosis Factor Alpha Blockers for Inflammatory Complications. Journal of Clinical Immunology, 2021, 41, 185-193.	3.8	15
8	Cerebral histoplasmosis caused by $\langle i \rangle$ Histoplasma capsulatum $\langle i \rangle$ var. $\langle i \rangle$ duboisii $\langle i \rangle$ in a patient with no known immunodeficiency. Journal of Travel Medicine, 2021, 28, .	3.0	5
9	Cryptococcal Antigen in Serum and Cerebrospinal Fluid for Detecting Cryptococcal Meningitis in Adults Living With Human Immunodeficiency Virus: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies. Clinical Infectious Diseases, 2021, 72, 1268-1278.	5.8	51
10	Stewardship program on carbapenem prescriptions in a tertiary hospital for adults and children in France: a cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1039-1048.	2.9	5
11	Fungal Burden and Raised Intracranial Pressure Are Independently Associated With Visual Loss in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis. Open Forum Infectious Diseases, 2021, 8, ofab066.	0.9	6
12	Risk of Lung Allograft Dysfunction Associated With Aspergillus Infection. Transplantation Direct, 2021, 7, e675.	1.6	9
13	Cryptococcus gattii in Patients with Lymphoid Neoplasms: An Illustration of Evolutive Host–Fungus Interactions. Journal of Fungi (Basel, Switzerland), 2021, 7, 212.	3.5	4
14	Current Spectrum of Infections in Patients with X-Linked Agammaglobulinemia. Journal of Clinical Immunology, 2021, 41, 1266-1271.	3.8	6
15	Azole Susceptibility Profiles of More than 9,000 Clinical Yeast Isolates Belonging to 40 Common and Rare Species. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	17
16	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Medicine, 2021, 47, 819-834.	8.2	106
17	Evaluation of a New Histoplasma spp. Quantitative RT-PCR Assay. Journal of Molecular Diagnostics, 2021, 23, 698-709.	2.8	25
18	Humans with inherited TÂcell CD28 deficiency are susceptible to skin papillomaviruses but are otherwise healthy. Cell, 2021, 184, 3812-3828.e30.	28.9	53

#	Article	IF	Citations
19	Short-term Mortality Outcomes of HIV-Associated Cryptococcal Meningitis in Antiretroviral Therapy–NaÃ⁻ve and –Experienced Patients in Sub-Saharan Africa. Open Forum Infectious Diseases, 2021, 8, ofab397.	0.9	9
20	Morocco as a possible source for acquisition of Rhinocladiella mackenziei. PLoS Neglected Tropical Diseases, 2021, 15, e0009563.	3.0	5
21	When to change treatment of acute invasive aspergillosis: an expert viewpoint. Journal of Antimicrobial Chemotherapy, 2021, 77, 16-23.	3.0	15
22	Procalcitonin use for the screening of bacterial infections in pregnant women in the emergency ward: A prospective study. Journal of Infection, 2021, 83, e4-e5.	3.3	0
23	One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi. Clinical Infectious Diseases, 2020, 70, 521-524.	5.8	13
24	Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis. Clinical Infectious Diseases, 2020, 70, 26-29.	5.8	13
25	Devastating Gynecological Infections in Women with STAT3 Deficiency. Clinical Infectious Diseases, 2020, 71, e186-e190.	5.8	3
26	Chronic Disseminated Candidiasis During Hematological Malignancies: An Immune Reconstitution Inflammatory Syndrome With Expansion of Pathogen-Specific T Helper Type 1 Cells. Journal of Infectious Diseases, 2020, 221, 1907-1916.	4.0	13
27	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. Leukemia, 2020, 34, 1090-1101.	7.2	34
28	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
29	Smoking as a Risk Factor of Invasive Fungal Disease: Systematic Review and Meta-Analysis. Clinical Infectious Diseases, 2020, 71, 1106-1119.	5.8	16
30	Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. Annals of the Rheumatic Diseases, 2020, 79, 1532-1543.	0.9	23
31	Voriconazole topical cream formulation: evidence for stability and antifungal activity. International Journal of Antimicrobial Agents, 2020, 56, 106083.	2.5	10
32	A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV-associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration. Aids, 2020, 34, 1425-1428.	2.2	9
33	Diagnostic Accuracy of the Biosynex CryptoPS Cryptococcal Antigen Semiquantitative Lateral Flow Assay in Patients with Advanced HIV Disease. Journal of Clinical Microbiology, 2020, 59, .	3.9	10
34	Nocardiosis Associated with Primary Immunodeficiencies (Nocar-DIP): an International Retrospective Study and Literature Review. Journal of Clinical Immunology, 2020, 40, 1144-1155.	3.8	11
35	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Medicine, 2020, 46, 1524-1535.	8.2	278
36	Failure of multiplex meningitis/encephalitis (ME) NAT during cryptococcal meningitis in solid organ recipients. Transplant Infectious Disease, 2020, 22, e13263.	1.7	6

3

#	Article	IF	CITATIONS
37	"Chronic Disseminated Aspergillosis,―a Novel Fungal Immune Reconstitution Inflammatory Syndrome. Open Forum Infectious Diseases, 2020, 7, ofaa175.	0.9	2
38	Emergence of azole resistant-Aspergillus fumigatus infections during STAT3-deficiency. Journal of Medical Microbiology, 2020, 69, 844-849.	1.8	5
39	Impact of Routine Cryptococcal Antigen Screening and Targeted Preemptive Fluconazole Therapy in Antiretroviral-naive Human Immunodeficiency Virus–infected Adults With CD4 Cell Counts <100/Î⅓L: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2019, 68, 688-698.	5.8	38
40	A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency. Journal of Clinical Immunology, 2019, 39, 702-712.	3.8	3
41	Isavuconazole Diffusion in Infected Human Brain. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	24
42	Low Central Nervous System Posaconazole Concentrations during Cerebral Phaeohyphomycosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	18
43	Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2387-2395.e3.	3.8	42
44	New Insights Into Cryptococcus Spp. Biology and Cryptococcal Meningitis. Current Neurology and Neuroscience Reports, 2019, 19, 81.	4.2	13
45	Teaching Neurolmages: Aspergillosis-induced vasculitis presenting as ischemic stroke in an immunocompetent patient. Neurology, 2019, 92, e2618-e2619.	1.1	1
46	Defining standards of CARE for invasive fungal diseases in solid organ transplant patients. Journal of Antimicrobial Chemotherapy, 2019, 74, ii16-ii20.	3.0	4
47	Non-Aspergillus Fungal Infections in Chronic Granulomatous Disease. Current Fungal Infection Reports, 2019, 13, 59-66.	2.6	3
48	Fulminant arterial vasculitis as an unusual complication of disseminated staphylococcal disease due to the emerging CC1 methicillin-susceptible Staphylococcus aureus clone: a case report. BMC Infectious Diseases, 2019, 19, 302.	2.9	3
49	Why are so many cases of invasive aspergillosisÂmissed?. Medical Mycology, 2019, 57, S94-S103.	0.7	33
50	Healthcare Costs and Life-years Gained From Treatments Within the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) Trial on Cryptococcal Meningitis: A Comparison of Antifungal Induction Strategies in Sub-Saharan Africa. Clinical Infectious Diseases, 2019, 69, 588-595.	5.8	18
51	AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study. BMJ Open, 2019, 9, e026288.	1.9	6
52	Progressive Multifocal Leukoencephalopathy in Primary Immunodeficiencies. Journal of Clinical Immunology, 2019, 39, 55-64.	3.8	20
53	Intestinal dysbiosis in inflammatory bowel disease associated with primary immunodeficiency. Journal of Allergy and Clinical Immunology, 2019, 143, 775-778.e6.	2.9	28
54	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 81-87.	3.8	42

#	Article	IF	CITATIONS
55	Successful Treatment of <i>Saksenaea</i> sp. Osteomyelitis by Conservative Surgery and Intradiaphyseal Incorporation of Amphotericin B Cement Beads. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	8
56	Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. Lancet Infectious Diseases, The, 2019, 19, e143-e147.	9.1	63
57	Mainly Post-Transplant Factors Are Associated with Invasive Aspergillosis after Allogeneic Stem Cell Transplantation: A Study from the Surveillance des Aspergilloses Invasives en France and Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Biology of Blood and Marrow Transplantation. 2019. 25. 354-361.	2.0	23
58	Recent advances in managing HIV-associated cryptococcal meningitis. F1000Research, 2019, 8, 743.	1.6	11
59	Long term mortality and disability in Cryptococcal Meningitis: a systematic literature review Clinical Infectious Diseases, 2018, 66, 1122-1132.	5.8	53
60	Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 757-763.	3.0	40
61	Fulminant Nocardiosis Due to a Multidrug-Resistant Isolate in a 12-Year-Old Immunocompetent Child. Pediatrics, 2018, 141, .	2.1	15
62	Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. New England Journal of Medicine, 2018, 378, 1004-1017.	27.0	296
63	Severe dermatophytosis in solid organ transplant recipients: A French retrospective series and literature review. Transplant Infectious Disease, 2018, 20, e12799.	1.7	44
64	Recent advances in the understanding and management of mucormycosis. F1000Research, 2018, 7, 1429.	1.6	53
65	Understanding Pathogenesis and Care Challenges of Immune Reconstitution Inflammatory Syndrome in Fungal Infections. Journal of Fungi (Basel, Switzerland), 2018, 4, 139.	3.5	34
66	Recent advances in understanding and managing infectious diseases in solid organ transplant recipients. F1000Research, 2018, 7, 661.	1.6	7
67	Failure of voriconazole therapy due to acquired azole resistance in Aspergillus fumigatus in a kidney transplant recipient with chronic necrotizing aspergillosis. American Journal of Transplantation, 2018, 18, 2352-2355.	4.7	14
68	ls It Time for Systematic Voriconazole Pharmacogenomic Investigation for Central Nervous System Aspergillosis?. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	8
69	Salvage Strategy for Long-Term Central Venous Catheter-Associated Staphylococcus aureus Infections in Children. Frontiers in Pediatrics, 2018, 6, 427.	1.9	12
70	Omalizumab: Efficacy and Safety in Mast Cell Disorders. Blood, 2018, 132, 4280-4280.	1.4	0
71	Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet, The, 2017, 389, 612-620.	13.7	95
72	Legionnaire's Disease in Compromised Hosts. Infectious Disease Clinics of North America, 2017, 31, 123-135.	5.1	28

#	Article	IF	CITATIONS
73	Impact of echinocandin on prognosis of proven invasive candidiasis in ICU: A post-hoc causal inference model using the AmarCAND2 study. Journal of Infection, 2017, 74, 408-417.	3.3	13
74	An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1046, 26-33.	2.3	32
75	Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 510-519.	9.1	366
76	Chronic pulmonary aspergillosis complicating sarcoidosis. European Respiratory Journal, 2017, 49, 1602396.	6.7	66
77	Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. Journal of Autoimmunity, 2017, 80, 10-27.	6.5	114
78	Predisposing factors and outcome of uncommon yeast species-related fungaemia based on an exhaustive surveillance programme (2002–14). Journal of Antimicrobial Chemotherapy, 2017, 72, 1784-1793.	3.0	57
79	The risk and clinical outcome of candidemia depending on underlying malignancy. Intensive Care Medicine, 2017, 43, 652-662.	8.2	92
80	Acute reversible pancreatitis induced by posaconazole. Journal of Antimicrobial Chemotherapy, 2017, 72, 628-630.	3.0	6
81	Arboviruses and pregnancy: maternal, fetal, and neonatal effects. The Lancet Child and Adolescent Health, 2017, 1, 134-146.	5.6	80
82	Thalidomide for steroidâ€dependent chronic disseminated candidiasis after stem cell transplantation: A case report. Transplant Infectious Disease, 2017, 19, e12637.	1.7	4
83	Cryptococcal meningitis: A neglected NTD?. PLoS Neglected Tropical Diseases, 2017, 11, e0005575.	3.0	47
84	Severe Dermatophytosis and Acquired or Innate Immunodeficiency: A Review. Journal of Fungi (Basel,) Tj ETQq0	O 03.gBT /0	Overlock 10 T
85	Rifabutin: where do we stand in 2016?. Journal of Antimicrobial Chemotherapy, 2016, 71, 1759-1771.	3.0	61
86	The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and) Tj ETQq0 0 0 rgBT /Over	ock 10 Tf	50 ₁ 222 Td (n
87	Prognosis of Invasive Aspergillosis in Kidney Transplant Recipients: A Case-Control Study. Transplantation Direct, 2016, 2, e90.	1.6	12
88	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet, The, 2016, 387, 760-769.	13.7	695
89	Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial. Journal of Antimicrobial Chemotherapy, 2016, 71, 783-793.	3.0	2
90	Inherited CARD9 deficiency in otherwise healthy children and adults with Candida species–induced meningoencephalitis, colitis, or both. Journal of Allergy and Clinical Immunology, 2015, 135, 1558-1568.e2.	2.9	208

#	Article	IF	Citations
91	Relevance of EORTC Criteria for the Diagnosis of Invasive Aspergillosis in HIV-Infected Patients, and Survival Trends Over a 20-Year Period in France. Clinical Infectious Diseases, 2015, 61, 1273-1280.	5.8	24
92	Polyvalent immunoglobulins in neonates after perinatal exposure to measles. Journal of Infection, 2015, 71, 131-134.	3.3	12
93	A neuropathological study of cerebrovascular abnormalities in a signal transducer and activator of transcription 3–deficient patient. Journal of Allergy and Clinical Immunology, 2015, 136, 1418-1421.e5.	2.9	5
94	Inherited CARD9 Deficiency in 2 Unrelated Patients With Invasive Exophiala Infection. Journal of Infectious Diseases, 2015, 211, 1241-1250.	4.0	141
95	Population-Based Analysis of Invasive Fungal Infections, France, 2001–2010. Emerging Infectious Diseases, 2014, 20, 1163-1169.	4.3	322
96	Association of mastocytosis with inflammatory joint diseases: A series of 31 patients. Seminars in Arthritis and Rheumatism, 2014, 44, 362-365.	3.4	12
97	Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome. Aids, 2014, 28, 1593-1602.	2.2	28
98	Liquid chromatography–tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 944, 175-181.	2.3	13
99	Aspergillus osteomyelitis: Epidemiology, clinical manifestations, management, and outcome. Journal of Infection, 2014, 68, 478-493.	3.3	93
100	Epidemiology and clinical management of Legionnaires' disease. Lancet Infectious Diseases, The, 2014, 14, 1011-1021.	9.1	314
101	Fungal endocarditis: current challenges. International Journal of Antimicrobial Agents, 2014, 44, 290-294.	2.5	79
102	Systemic Inflammatory and Autoimmune Diseases (SAID) Associated with MDS: A French Multicenter Retrospective Study. Blood, 2014, 124, 3254-3254.	1.4	0
103	Prognostic Factors of Infections and Effect of Primary Anti-Infectious Prophylaxis in MDS Patients Treated with Azacitidine (AZA): A Prospective Study. Blood, 2014, 124, 1917-1917.	1.4	0
104	Deep Dermatophytosis and Inherited CARD9 Deficiency. New England Journal of Medicine, 2013, 369, 1704-1714.	27.0	362
105	Efficacy and safety of thalidomide in patients with inflammatory manifestations of chronic granulomatous disease: AÂretrospective case series. Journal of Allergy and Clinical Immunology, 2013, 132, 997-1000.e4.	2.9	26
106	Primary immunodeficiencies underlying fungal infections. Current Opinion in Pediatrics, 2013, 25, 736-747.	2.0	190
107	Fungal Infections in Immunocompromised Travelers. Clinical Infectious Diseases, 2013, 56, 861-869.	5.8	39
108	Incidence and Risk Factors of Legionella pneumophila Pneumonia During Anti-Tumor Necrosis Factor Therapy. Chest, 2013, 144, 990-998.	0.8	75

#	Article	IF	CITATIONS
109	Risk of Herpes Zoster in Patients Receiving Anti-TNF- \hat{l}_{\pm} in the Prospective French RATIO Registry. Journal of Investigative Dermatology, 2012, 132, 726-729.	0.7	46
110	Autosomal Dominant STAT3 Deficiency and Hyper-IgE Syndrome. Medicine (United States), 2012, 91, e1-e19.	1.0	274
111	Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS. Aids, 2012, 26, 2110-2112.	2.2	62
112	French-Brazilian Survey On Pregnancy in Sickle Cell Disease A Study of the International Sickle Cell Disease Observatory. Blood, 2012, 120, 3215-3215.	1.4	0
113	Development and Validation of a Sensitive Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Assay for the Simultaneous Quantification of Midostaurin (PKC412) and Its Two Major Metabolites: A Suitable Tool for the Monitoring of the Drug in Patients Suffering From Advanced Systemic Mastocytosis, Blood, 2012, 120, 4913-4913.	1.4	3
114	Mycobacterium genavense as a cause of subacute pneumonia in patients with severe cellular immunodeficiency. BMC Infectious Diseases, 2011, 11, 311.	2.9	19
115	Gain-of-function human <i>STAT1</i> mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. Journal of Experimental Medicine, 2011, 208, 1635-1648.	8.5	739
116	Imported Acquired Immunodeficiency Syndrome–Related Histoplasmosis in Metropolitan France: A Comparison of Pre–Highly Active Anti-Retroviral Therapy and Highly Active Anti-Retroviral Therapy Eras. American Journal of Tropical Medicine and Hygiene, 2011, 85, 934-941.	1.4	40
117	Thalidomide in Advanced Mastocytosis. Results from an Open-Label, Multicentric, Phase II Study. Blood, 2011, 118, 1754-1754.	1.4	3
118	International Retrospective Analysis of 73 Cases of Invasive Fusariosis Treated with Voriconazole. Antimicrobial Agents and Chemotherapy, 2010, 54, 4446-4450.	3.2	158
119	Cerebral Phaeohyphomycosis Caused by <i>Rhinocladiella mackenziei</i> in a Woman Native to Afghanistan. Journal of Clinical Microbiology, 2010, 48, 3451-3454.	3.9	33
120	Granulocyte Colony Stimulating Factor-induced Exacerbation of Fungus-related Immune Restoration Inflammatory Syndrome: A Case of Chronic Disseminated Candidiasis Exacerbation. Journal of Microbiology, Immunology and Infection, 2010, 43, 339-343.	3.1	12
121	Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2010, 50, 291-322.	5.8	2,195
122	Long Term Efficacy and Safety of Cladribine In Adult Systemic mastocytosis: a French Multicenter Study of 44 Patients. Blood, 2010, 116, 1982-1982.	1.4	12
123	Zygomycosis After Allogeneic Hematopoietic Stem Cell Transplantation: A French Multicenter Cohort Study (2003-2008). Blood, 2010, 116, 1263-1263.	1.4	8
124	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 2008, 46, 1813-1821.	5 . 8	4,375
125	Immunocompromised Hosts: Cryptococcosis in Solid Organ Transplant Recipients: Current State of the Science. Clinical Infectious Diseases, 2008, 47, 1321-1327.	5.8	202
126	Adjuvant Corticosteroid Therapy for Chronic Disseminated Candidiasis. Clinical Infectious Diseases, 2008, 46, 696-702.	5.8	140

#	Article	lF	CITATIONS
127	Determinants of Disease Presentation and Outcome during Cryptococcosis: The CryptoA/D Study. PLoS Medicine, 2007, 4, e21.	8.4	338
128	Cryptococcus neoformansin Organ Transplant Recipients: Impact of Calcineurinâ€Inhibitor Agents on Mortality. Journal of Infectious Diseases, 2007, 195, 756-764.	4.0	243
129	Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. Aids, 2006, 20, 119-121.	2.2	93
130	Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. Aids, 2005, 19, 1043-1049.	2.2	289
131	Allograft Loss in Renal Transplant Recipients with Cryptococcus Neoformans Associated Immune Reconstitution Syndrome. Transplantation, 2005, 80, 1131-1133.	1.0	95
132	An Immune Reconstitution Syndrome-Like Illness Associated with Cryptococcus neoformans Infection in Organ Transplant Recipients. Clinical Infectious Diseases, 2005, 40, 1756-1761.	5.8	243
133	Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis. New England Journal of Medicine, 2002, 347, 408-415.	27.0	3,048
134	Invasive aspergillosis in patients with acquired immunodeficiency syndrome: Report of 33 cases. American Journal of Medicine, 1993, 95, 177-187.	1.5	203